Nyheter & Information
Läs de senaste produktnyheterna och erbjudandena här
Planera för kalibrering av dina detektorer.
November 21st/22nd 2022.
Effective April 2022, the Lucigen brand will start its final phases of transitioning to Biosearch Technologies, LGC’s comprehensive genomics portfolio. They are making this change because Biosearch Technologies unifies all legacy brands under one collective offer. This allows them to provide consistency across all of their products and services so they can deliver optimal support across our customers’ entire genomics workflow and at every stage of their product development pipeline.
A technology to improve patient care.
Antibody based drugs can disturb serological blood group testing since the examined antigens can be masked by the therapeutic antibodies. An anti-CD38 antibody for treatment of multiple myeloma shows a strong interference in the indirect antiglobulin test (IAT) where most of the reactions turn to unspecifically (wrong) positive. The time consuming standard technique using Dithiothreitol (DTT) counteracts the interference but has major drawbacks like destruction of Kel antigens or hemolysis. The imusyn DaraEx compound inhibits the agglutination effect of anti-CD38 in IAT without side effects.
Här presenteras information om nya samarbetspartners och lösningar som vi hoppas ska kunna lanseras under 2022.